May 07, 2021

Incyte Pays 12.6 Million to Resolve Allegation for Paying Kickbacks

Incyte Corporation, a Delaware based pharmaceutical company, has agreed to pay $12.6 million to resolve allegations that it violated the False Claims Act by paying kickbacks. From November 2011 through December 2014, Incyte used an independent foundation as a conduit to pay the copays of certain federal beneficiaries taking Incyte’s drug, Jakafi, which was approved to treat myelofibrosis in 2011. Incyte pressured the foundation, through phone calls and emails, to provide assistance to ineligible patients, and a contractor for Incyte helped ineligible patients to complete applications submitted to the fund for assistance.